Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection.
about
The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaBViruses associated with human cancerEpstein-barr virus sequence variation-biology and diseaseEpstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirusThe genetic approach to the Epstein-Barr virus: from basic virology to gene therapy.Identification of B cells as a major site for cyprinid herpesvirus 3 latency.Molecular virology of Epstein-Barr virus.EBNA3C coactivation with EBNA2 requires a SUMO homology domain.Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes.Epstein-Barr Virus Proteins EBNA3A and EBNA3C Together Induce Expression of the Oncogenic MicroRNA Cluster miR-221/miR-222 and Ablate Expression of Its Target p57KIP2.The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues.Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs.The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation.Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocyte growth transformation.An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitroEpstein-Barr virus recombinants from overlapping cosmid fragments.The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro.Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation.Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitroA selectable marker allows investigation of a nontransforming Epstein-Barr virus mutantEpstein-Barr virus (EBV)-negative B-lymphoma cell lines for clonal isolation and replication of EBV recombinants.Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus.Epstein-Barr virus vectors for gene delivery to B lymphocytes.Structural, functional, and genetic comparisons of Epstein-Barr virus nuclear antigen 3A, 3B, and 3C homologues encoded by the rhesus lymphocryptovirus.The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformationInitiation of DNA replication within oriP is dispensable for stable replication of the latent Epstein-Barr virus chromosome after infection of established cell lines.Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells.Epstein-Barr virus nuclear antigen (EBNA) 3A induces the expression of and interacts with a subset of chaperones and co-chaperones.
P2860
Q24646694-F577915E-96C4-412A-81FB-58BFBDCBBF29Q24653900-CBDAD33E-71E6-421A-89C9-EDAB37EDF7CEQ27003183-F99B78EA-0662-4791-AC41-0E5D9E675317Q33796173-6784CBAA-BE38-4951-9F30-604E57B81BE4Q33918592-BB8B78A5-D8DE-44BC-ADE6-EAC821951C9CQ34059245-A9636BFC-8415-43D4-A293-E2FCB483204DQ34225554-258473A3-2EAB-427F-9C80-DFDAACAD5788Q34552733-667E5C8E-A623-4251-A3FB-32203A97313DQ34985686-2890ECFF-1A50-4265-9BE3-C0631E801898Q35685797-42D4B0BE-049F-47FB-97CB-4E984A6AF1F8Q35831016-7961410F-59A2-4B9C-A1BD-C90F93F916A1Q35832104-183BEF1C-9058-4430-9096-DC1B6037A4E3Q35997566-D8DE48E5-B698-4767-AE20-0710D26C55BEQ36575274-B503686E-4E50-422A-B66B-D22125A5F23DQ36622140-F078419C-EFA6-4982-8BCF-0235764676E8Q36628631-8D4D045A-C749-40E8-8996-23BAC7DFB3CEQ36655212-F0DAA998-7619-4742-8C16-BA21B6C2E1C1Q36685081-2D182707-EF60-4D4E-82DB-3D92BCD8D7C2Q36686042-14713C42-F1E5-48D5-9F6D-9766900D98FFQ36686055-0F9DAA92-F627-47B0-98AB-D8912176C22EQ36697392-FD105058-8BBD-4F7C-A152-E9A823352E11Q36697700-0AD69503-1C2F-4939-BE1A-430864B21737Q36700868-DC766514-CEF0-47C7-90E7-7AAB8CC00882Q36849568-9E85B4F0-4105-494F-91DA-D1320EA8B8AEQ37248930-8CC7969F-F3C1-46A3-B3A0-8BC6C38A3C0FQ39591670-2A5CE0F1-9481-4E5B-86CB-0E6B6298D0B5Q39596927-78B0BFB6-C784-475D-8824-E6AA596AC8AAQ39612332-1348BEAE-4281-4225-9C69-9371EF30EB9CQ39876626-561A6B1A-5EBD-4EA3-B897-3AE0D981ECAEQ40002001-53E33307-7213-427D-A372-414DC100B58A
P2860
Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Second-site homologous recombi ...... effect on in vitro infection.
@ast
Second-site homologous recombi ...... effect on in vitro infection.
@en
type
label
Second-site homologous recombi ...... effect on in vitro infection.
@ast
Second-site homologous recombi ...... effect on in vitro infection.
@en
prefLabel
Second-site homologous recombi ...... effect on in vitro infection.
@ast
Second-site homologous recombi ...... effect on in vitro infection.
@en
P2860
P1433
P1476
Second-site homologous recombi ...... effect on in vitro infection.
@en
P2093
B Tomkinson
P2860
P304
P407
P577
1992-02-01T00:00:00Z